Aclaris Therapeutics Ownership
| ACRS Stock | USD 2.48 0.09 3.77% |
Shares in Circulation | First Issued 2014-09-30 | Previous Quarter 71.3 M | Current Value 71.4 M | Avarage Shares Outstanding 42.3 M | Quarterly Volatility 20.1 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Aclaris |
Aclaris Stock Ownership Analysis
About 59.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.97. Some equities with similar Price to Book (P/B) outperform the market in the long run. Aclaris Therapeutics recorded a loss per share of 0.52. The entity had not issued any dividends in recent years. Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania. Aclaris Therapts operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 72 people. For more info on Aclaris Therapeutics please contact the company at 484 324 7933 or go to https://www.aclaristx.com.Besides selling stocks to institutional investors, Aclaris Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Aclaris Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Aclaris Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Aclaris Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Aclaris Therapeutics Insider Trades History
Roughly 3.0% of Aclaris Therapeutics are currently held by insiders. Unlike Aclaris Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Aclaris Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Aclaris Therapeutics' insider trades
Aclaris Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Aclaris Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Aclaris Therapeutics backward and forwards among themselves. Aclaris Therapeutics' institutional investor refers to the entity that pools money to purchase Aclaris Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Deutsche Bank Ag | 2024-09-30 | 923.3 K | Jacobs Levy Equity Management, Inc. | 2024-09-30 | 915.5 K | Two Sigma Investments Llc | 2024-09-30 | 907.9 K | Geode Capital Management, Llc | 2024-09-30 | 846.4 K | Samsara Biocapital, Llc | 2024-09-30 | 696.2 K | Acuitas Investments, Llc | 2024-09-30 | 578.1 K | Palo Alto Investors, Llc | 2024-09-30 | 569.8 K | Fmr Inc | 2024-09-30 | 546 K | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 480.8 K | Bml Capital Management Llc | 2024-09-30 | 14.2 M | Vanguard Group Inc | 2024-09-30 | 4.7 M |
Aclaris Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Aclaris Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Aclaris Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Aclaris Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Aclaris Therapeutics Outstanding Bonds
Aclaris Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Aclaris Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Aclaris bonds can be classified according to their maturity, which is the date when Aclaris Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View |
Aclaris Therapeutics Corporate Filings
8K | 13th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 3rd of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 31st of December 2024 Other Reports | ViewVerify | |
| 19th of December 2024 Other Reports | ViewVerify |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Aclaris Stock Analysis
When running Aclaris Therapeutics' price analysis, check to measure Aclaris Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aclaris Therapeutics is operating at the current time. Most of Aclaris Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aclaris Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aclaris Therapeutics' price. Additionally, you may evaluate how the addition of Aclaris Therapeutics to your portfolios can decrease your overall portfolio volatility.